dc.contributor.author |
Mudduwa, L.K.B. |
|
dc.contributor.author |
Wijayaratne, G.B. |
|
dc.contributor.author |
Peiris, H.H. |
|
dc.contributor.author |
Gunasekera, S.N. |
|
dc.contributor.author |
Abeysiriwardhana, D. |
|
dc.contributor.author |
Liyanage, N. |
|
dc.date.accessioned |
2023-01-04T08:58:53Z |
|
dc.date.available |
2023-01-04T08:58:53Z |
|
dc.date.issued |
2018 |
|
dc.identifier.citation |
Mudduwa, L. K., Wijayaratne, G. B., Peiris, H. H., Gunasekera, S. N., Abeysiriwardhana, D., & Liyanage, N. (2018). Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis?. International Journal of Women's Health, 10, 329-335. |
en_US |
dc.identifier.uri |
http://ir.lib.ruh.ac.lk/xmlui/handle/iruor/10093 |
|
dc.description.abstract |
Background: CA15-3 is the most commonly used tumor marker in breast cancer. Its prognostic
role has been described in the metastatic setting, but the role of pre-surgical CA15-3 in the
assessment of patients with breast cancer without metastasis has not been substantiated yet.
Methodology: From February 2014 for a 2-year period, this prospective study included all
patients who were diagnosed with primary breast cancer and underwent surgery at a tertiary
care hospital. The serum level of CA15-3 was assessed on a pre-surgical blood sample and later
at the 3-, 6-, 9-, and 12-month follow-up by enzyme-linked immunosorbent assay. Disease-free
survival (DFS) was analyzed with a Kaplan–Meier model and log-rank test.
Results: We enrolled 195 patients (mean age ± SD 57.84 years ±13.819, range, 28–95) with
breast cancer. The prevalence of elevated ($30 U/mL) pre-surgical CA15-3 was 35.9%, and it
reduced to 14.3% at 3 months after mastectomy. Pre-surgical CA15-3 had a significant associa tion only with the size of the tumor (p=0.047). Patients who did not have elevated pre-surgical
CA15-3 ($30 U/mL) had the best short-term DFS, and it was worst when the pre-surgical
CA15-3 was .100 U/mL (p=0.041).
Conclusion: Elevated pre-surgical CA15-3 is a predictor of poor short-term DFS of patients
with breast cancer without distant metastasis. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
International Journal of Women's Health |
en_US |
dc.subject |
Breast cancer |
en_US |
dc.subject |
Pre-surgical CA15-3 |
en_US |
dc.subject |
Short-term disease-free survival |
en_US |
dc.subject |
Prognosis |
en_US |
dc.title |
Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis? |
en_US |
dc.type |
Article |
en_US |